When ATN-RNA, a double-stranded RNA complementary to human tenascin C, was applied locally to patients with advance brain tumors, the drug showed a survival benefit of 18 weeks in grade III astrocytoma and 10 weeks in glioblastoma multiforme (144). Here, TNC is linked to astrocytoma (excluding glioblastoma).